In the context of multi-country Real-World Evidence (RWE) studies, “Regulatory Compliance Maps” are essentially a detailed representation of the diverse regulatory requirements specific to each participating country.
RWE studies involve the analysis of data derived from a number of different sources outside of typical clinical trials, such as electronic health records (EHRs), medical claims and billing data, patient registries, and patient-generated data. Different countries have varied regulations regarding the use and sharing of such data, including the handling of patient privacy, data security, and informed consent among others.
To navigate through this complex landscape, regulatory compliance maps are created for several purposes:
[1] Understanding the Regulation: These maps help in identifying the specific regulatory requirements in each country. They define how to handle, process, store, and share patient data.
[2] Comparison: They also provide a comparative view of the regulatory landscape across different countries. This comparison allows companies to understand the relative complexity of conducting RWE studies in different regions.
[3] Planning: Based on these compliance maps, companies can strategise and design their RWE studies to ensure they meet all regulatory requirements. This might involve altering the study design or selecting specific data collection tools in different regions.
[4] Risk Mitigation: By understanding the specific regulations in each region, companies can take proactive steps to minimize risks associated with non-compliance, which might lead to legal repercussions or reputational damage.
[5] Collaboration: These maps also facilitate better communication and cooperation with local authorities, including IRBs/RECs, as they demonstrate the company’s understanding and respect for local regulations.
Creating and maintaining regulatory compliance maps can be a complex task due to the evolving nature of regulations, the diversity of data sources, and the need for expertise in different jurisdictional laws. However, it is an essential part of conducting efficient and ethical multi-country RWE studies.
Share this story...
Real World Evidence (RWE) 101 – Patient Retention
RWE 101 - Patient Retention Long-term Real-World Evidence (RWE) studies face significant challenges when it comes to patient retention, for several reasons:[1] Time Commitment: Participants in RWE studies are [...]
Real World Evidence (RWE) 101 – Patient Recruitment
RWE 101 - Patient Recruitment Real-world evidence (RWE) is health care information derived from real-world data (RWD). It can be generated through various study designs or analyses, including pragmatic [...]
Real World Evidence (RWE) 101 – HARPER
RWE 101 - HARPER Regulatory agencies, health technology assessors, and payers are increasingly interested in studies that make use of real-world data to inform regulatory and other policy or [...]
Real World Evidence (RWE) 101 – STaRT-RWE
RWE 101 - STaRT-RWE START-RWE (Structured Template for Planning and Reporting on the Implementation of Real World Evidence Studies) was developed to address the need for improved transparency and [...]
Real World Evidence (RWE) 101 – Protocol Design and ISPE GPP
RWE 101 - Protocol Design and ISPE GPP The International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP) are a set of best practices for the conduct [...]
Real World Evidence (RWE) 101 – Protocol Design and Scientific Best Practices
RWE 101 - Protocol Design and Scientific Best Practices Designing a robust Real-World Evidence (RWE) study is crucial for generating reliable and valid insights that are acceptable to regulators. [...]







